Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...

MOE Key Laboratory of Gene Function and Regulation, Guangdong Province Key Laboratory of Pharmaceutical Functional Genes, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen ...

Argent BioPharma , a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through ...

Host-pathogen interactions are dynamic processes that encompass the techniques employed by pathogens to infect and overcome immune systems, as well as the ...

India is developing a framework for over-the-counter (OTC) drugs, potentially allowing some prescription medications to be sold in general stores. A sub-committee is reviewing international guidelines ...

(Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat ... and impaired immune function, while the elevated IgM levels may ...

Introduction: Although rituximab is approved for several autoimmune diseases, no formal dose finding studies have been conducted ... We estimated terminal elimination half-lives of rituximab using the ...

In addition to Fast Track and Breakthrough Therapy Designations, MOLBREEVI has been granted Orphan Drug Designation for ... Regulatory Agency (MHRA). About Autoimmune PAP Autoimmune PAP is a ...

About Immunova, LLC Immunova is a privately held biotechnology company based in Connecticut, specializing in the development of lipid-based drugs and immune-modulating therapies. Immunova’s ...